Anteris Technologies Global (NASDAQ:AVR) Given “Overweight” Rating at Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Wednesday, Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 147.93% from the company’s previous close.

Several other analysts have also weighed in on AVR. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Barclays upgraded Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Anteris Technologies Global currently has an average rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Stock Performance

Shares of NASDAQ:AVR traded down $0.31 on Wednesday, hitting $6.05. The company’s stock had a trading volume of 1,032,918 shares, compared to its average volume of 1,122,214. Anteris Technologies Global has a 12 month low of $3.30 and a 12 month high of $11.06. The company has a market capitalization of $589.62 million, a price-to-earnings ratio of -3.10 and a beta of 1.87. The stock’s 50-day moving average is $8.24 and its two-hundred day moving average is $8.06.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period in the previous year, the company posted ($0.58) EPS. Equities analysts expect that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the business’s stock in a transaction dated Tuesday, October 6th. The stock was acquired at an average price of $7.18 per share, for a total transaction of $1,957,950.10. Following the completion of the acquisition, the insider directly owned 6,358,271 shares in the company, valued at $45,652,385.78. This represents a 4.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders acquired 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. 4.50% of the stock is currently owned by company insiders.

Institutional Trading of Anteris Technologies Global

Several institutional investors have recently modified their holdings of AVR. Farther Finance Advisors LLC lifted its holdings in shares of Anteris Technologies Global by 26,789.3% in the third quarter. Farther Finance Advisors LLC now owns 15,058 shares of the company’s stock valued at $117,000 after buying an additional 15,002 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $33,325,850. One68 Global Capital LLC acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $128,000. Bank of America Corp DE purchased a new stake in shares of Anteris Technologies Global during the second quarter valued at $1,907,000. Finally, AWM Investment Company Inc. purchased a new stake in shares of Anteris Technologies Global during the second quarter valued at $1,133,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.